Literature DB >> 20217102

A new preclinical femoral head osteonecrosis model in sheep.

Roberto Vélez1, Francisco Soldado, Alberto Hernández, Ignasi Barber, Marius Aguirre.   

Abstract

INTRODUCTION: Animal models have been used as insight into the pathogenesis of osteonecrosis, even though most have failed to reproduce all stages of human disease, limiting progression in experimental treatment modalities. A new surgically induced animal model of femoral head osteonecrosis in sheep is presented.
METHOD: Osteonecrosis was achieved using an improved method of intracephalic cryogenic lesion by means of a cryoprobe and vascular ligation.
RESULTS: Histologic findings at 6 and 12 weeks showed progression to advanced stage osteonecrosis. MRI, the gold standard in diagnosis and follow-up in human osteonecrosis showed concordant results with histology.
CONCLUSION: Our model can therefore be used as a preclinical femoral head osteonecrosis model in an easily accessible animal to assess biological treatments with MRI.

Entities:  

Mesh:

Year:  2010        PMID: 20217102     DOI: 10.1007/s00402-010-1084-5

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  11 in total

1.  Development of a mouse model of ischemic osteonecrosis.

Authors:  Nobuhiro Kamiya; Ryosuke Yamaguchi; Olumide Aruwajoye; Naga Suresh Adapala; Harry K W Kim
Journal:  Clin Orthop Relat Res       Date:  2015-02-10       Impact factor: 4.176

Review 2.  Animal models of steroid-induced osteonecrosis of the femoral head-a comprehensive research review up to 2018.

Authors:  Jianzhong Xu; Hanpu Gong; Shitao Lu; Matthey J Deasey; Quanjun Cui
Journal:  Int Orthop       Date:  2018-04-28       Impact factor: 3.075

3.  New preclinical porcine model of femoral head osteonecrosis to test mesenchymal stromal cell efficiency in regenerative medicine.

Authors:  Alexandre Poignard; Angélique Lebouvier; Madeleine Cavet; Alain Rahmouni; Charles-Henri Flouzat Lachaniette; Philippe Bierling; Hélène Rouard; Philippe Hernigou; Nathalie Chevallier
Journal:  Int Orthop       Date:  2014-05-09       Impact factor: 3.075

Review 4.  Experimental animal models of osteonecrosis.

Authors:  Meng Fan; Jiang Peng; Ling Qin; Shibi Lu
Journal:  Rheumatol Int       Date:  2011-02-22       Impact factor: 2.631

5.  Bone marrow oedema on MR imaging indicates ARCO stage 3 disease in patients with AVN of the femoral head.

Authors:  Reinhard Meier; Tobias M Kraus; Christoph Schaeffeler; Sebastian Torka; Anna Melissa Schlitter; Katja Specht; Bernhard Haller; Simone Waldt; Hans Rechl; Ernst J Rummeny; Klaus Woertler
Journal:  Eur Radiol       Date:  2014-05-28       Impact factor: 5.315

6.  A simple method for establishing an ostrich model of femoral head osteonecrosis and collapse.

Authors:  Wenxue Jiang; Pengfei Wang; Yanlin Wan; Dasen Xin; Meng Fan
Journal:  J Orthop Surg Res       Date:  2015-05-21       Impact factor: 2.359

7.  An animal model of early-stage femoral head osteonecrosis induced by cryo-insult in small tailed Han sheep.

Authors:  Cairu Wang; Zhigang Wu; Xiaokang Li; Lei Shi; Qingyun Xie; Da Liu; Zheng Guo; Wei Zheng
Journal:  J Orthop Translat       Date:  2020-09-28       Impact factor: 5.191

8.  Development of a clinically relevant animal model for the talar osteonecrosis in sheep.

Authors:  Chao-Fan Yuan; Jun-Lin Wang; Yong-Quan Zhang; Xiao-Kang Li; Yi Li; Su-Hua Wu; Zhi-Yong Zhang; Zheng Guo
Journal:  Int J Med Sci       Date:  2012-10-27       Impact factor: 3.738

9.  The treatment effect of porous titanium alloy rod on the early stage talar osteonecrosis of sheep.

Authors:  Xiao-Kang Li; Chao-Fan Yuan; Jun-Lin Wang; Yong-Quan Zhang; Zhi-Yong Zhang; Zheng Guo
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

10.  WNT-activated bone grafts repair osteonecrotic lesions in aged animals.

Authors:  B Salmon; B Liu; E Shen; T Chen; J Li; M Gillette; R C Ransom; M Ezran; C A Johnson; A B Castillo; W J Shen; F B Kraemer; A A Smith; J A Helms
Journal:  Sci Rep       Date:  2017-10-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.